MNKD Stock Analysis

MannKind Corp
HEALTHCARE BIOTECHNOLOGY

Back to Winners View Yahoo Finance Chart Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
F
31.77 / 100
Weak
Confidence: Very High (96.0%) Coverage: 96.0%
Business Quality 23.8
Financial Strength 28.3
Earnings & Growth 48.8
Valuation 33.8
Market Strength 24.3
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend SELL / AVOID TREND
Weak Trend
The current trend is unfavorable.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio 45.57
High Expectations
Very high P/E requires strong future results to justify the price.
P/E shows how much investors pay for each dollar of earnings.
ROIC 1.39%
Weak
Low ROIC suggests limited profit efficiency.
ROIC measures how efficiently capital turns into profit.
Debt Payback 23.26 yrs
Weak
A long payback period can raise financial-risk concerns.
Debt payback estimates how quickly debt could be covered.
Interest Coverage 2.81x
Weak
Low coverage can make debt more risky.
Interest coverage shows how easily earnings cover interest costs.
Price $3.19
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-25 00:28:17

Performance Overview

Trailing adjusted-close returns as of 2026-07-17. Benchmark is SPY.

YTD Return

MNKD -28.92%
SPY +9.58%

1-Year Return

MNKD +3.33%
SPY +19.66%

3-Year Return

MNKD -7.36%
SPY +71.13%

5-Year Return

MNKD -8.82%
SPY +84.41%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

0%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
FAIL

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
FAIL

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
SELL / AVOID TREND

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA3.35
50-Day MA3.65
200-Day MA3.79
MA Score0

Latest Published Stock Research

Research generated: October 24, 2026

MNKD Stock Analysis: Why MannKind Corp Scored 0% in Stock Value Finder

Analyzing MannKind Corp (MNKD): A Quantitative Deep Dive into Biotechnology Valuation and Capital Efficiency

This article serves as a comprehensive, educational StockValueFinder review of MannKind Corp (MNKD). The purpose of this research is to demonstrate how quantitative metrics are applied to evaluate a company's financial health, valuation, and capital efficiency. By examining the specific data points associated with MNKD, readers can learn how to interpret fundamental ratios and understand the mechanics of value-oriented stock screening. This is not a recommendation to trade, but rather a guide on how to use data to identify potential risks and strengths in the biotechnology sector.

Overview of MannKind Corp (MNKD)

MannKind Corp, trading under the ticker MNKD, operates within the Healthcare sector, specifically focusing on the Biotechnology industry. In the biotechnology space, companies often face unique financial profiles characterized by high research and development costs, significant capital requirements, and varying degrees of profitability. As a researcher, one must look past the scientific potential of a company's pipeline and focus on the cold, hard numbers that dictate whether a business can sustain its operations and protect shareholder purchasing power.

Currently, MNKD is trading at a recent price of $3.19. In an era where inflation and currency instability can erode the real value of capital, understanding whether a stock represents a productive use of money is essential. This review will dissect the company's metrics to determine if it meets the rigorous standards of a value-oriented investor.

Why the StockValueFinder Score Matters

The StockValueFinder score is a proprietary quantitative aggregate designed to provide an immediate snapshot of a company's fundamental alignment with value investing principles. For MannKind Corp, the StockValueFinder score is 0%, resulting in a rating of AVOID.

It is important for students of finance to understand that a 0% score does not necessarily mean a company has no assets or zero value; rather, it means the company failed to meet every single quantitative benchmark set by our screening criteria. In a hard-money perspective, we look for companies that demonstrate discipline, efficiency, and reasonable pricing. When a score is 0%, it indicates that the company's current financial profile—ranging from its valuation to its debt obligations—does not align with the criteria for a high-quality, value-oriented investment according to our model.

EPS Strength and Consistency

Earnings Per Share (EPS) is a fundamental metric representing the portion of a company's profit allocated to each outstanding share of common stock. Consistency in EPS is vital because it demonstrates a company's ability to generate actual cash flow and profit for its shareholders over time, rather than relying on erratic fluctuations.

Regarding the EPS test for MNKD, the system recorded a result of "Did not pass." While the specific historical EPS values were not supplied in this data set, the failure of the test indicates that the company's earnings history does not meet the required threshold for stability or growth as defined by our screening parameters.

To learn how to evaluate other stocks, consider this example: An investor might look for a company that has shown steady or increasing EPS over several years. A company with an EPS that fluctuates wildly between large profits and deep losses is often viewed as higher risk. In our screening process, if a company cannot demonstrate the necessary EPS strength, it fails this component of the fundamental analysis.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is a critical metric for assessing how effectively a company uses the money it has raised through debt and equity to generate profits. It is a measure of capital efficiency.

For MannKind Corp, the ROIC is 1.39%. StockValueFinder generally prefers an ROIC of 10% or higher. A high ROIC suggests that a company is a "compounding machine," able to take a dollar of capital and turn it into significantly more than a dollar over time. Conversely, a low ROIC suggests that capital is being deployed inefficiently.

To illustrate: A company with a 15% ROIC is using its capital much more effectively than a company with a 4% ROIC. The 15% company is generating more profit per dollar of investment, which is a hallmark of a high-quality business. Because MNKD’s ROIC of 1.39% is well below the 10% threshold, the system marked the ROIC test as "Did not pass."

Interest Coverage and Financial Safety

Interest coverage is a ratio used to determine how easily a company can pay the interest expenses on its outstanding debt. This is a vital metric for assessing solvency and the risk of bankruptcy during periods of economic volatility or rising interest rates.

The Interest coverage test for MNKD resulted in "Did not pass." StockValueFinder prefers an interest coverage ratio of 6 or higher. A high ratio provides a "margin of safety," ensuring that even if earnings dip, the company can still meet its obligations to lenders.

For example, a company with 8x interest coverage is in a much healthier position to weather an economic downturn than a company with only 2x coverage. A 2x coverage ratio means that most of the company's operating income is being consumed just to pay interest, leaving very little room for error. Because MNKD failed this test, it indicates a heightened level of financial risk regarding its ability to service debt.

Debt Payback and Balance Sheet Discipline

Debt payback refers to the number of years it would take for a company to pay off its total debt using its current earnings. This metric is a window into the long-term sustainability of a company's balance sheet and its exposure to debt-related risks.

MannKind Corp shows a debt payback period of 23.26 years. StockValueFinder prefers a debt payback of 3 years or less. A low debt payback period suggests that the company is not overly reliant on borrowed money and can quickly return to a state of high liquidity.

Consider this comparison: A debt payback of 1.5 years is highly attractive because it shows rapid deleveraging capability. A debt payback of 7 years is significantly more risky. At 23.26 years, MNKD's debt obligations are extremely long-term relative to its current earning power. Consequently, the system marked the debt payback test as "Did not pass."

P/E Ratio and Valuation Discipline

The Price-to-Earnings (P/E) ratio is a valuation metric that compares a company's current share price to its per-share earnings. It tells an investor how much they are paying for every $1 of profit the company generates.

The P/E ratio for MNKD is 45.57. For the purposes of maintaining valuation discipline, StockValueFinder prefers a P/E of 15 or lower. High P/E ratios often indicate that the market has priced in massive future growth expectations, which can lead to significant downside if those expectations are not met.

To provide an educational example: A P/E of 8 may be more value-oriented than a P/E of 40, assuming the underlying business quality is sound. A high P/E requires the company to perform perfectly to justify its price. Because MNKD's P/E of 45.57 is significantly higher than the target of 15, the P/E valuation test was marked as "Did not pass."

Moving Average Trend and Entry Timing

While fundamental analysis looks at the "what" and "why" of a company, technical indicators like moving averages are used to understand the "when"—the current momentum and trend of the stock price.

The moving average signal for MNKD is "SELL / AVOID TREND." Additionally, the entry signal is listed as "N/A." In professional research, a moving average trend is used for timing discipline; it is not a guarantee that a stock must rise or fall, but rather an observation of current market direction. An "Avoid Trend" suggests that the price action is currently moving in a direction that lacks upward momentum.

Regarding entry and risk levels, the following data points were not available

Limit buy idea: N/A - Pullback zone: N/A - Risk stop / trend risk level: N/A

These fields are intended to provide educational reference levels for where an investor might look for potential entries or exits. When they are "N/A," it means there are no specific mathematical levels provided by the system for this ticker at this time.

Overall Financial Strengths and Weaknesses

In summary, the quantitative profile of MannKind Corp (MNKD) presents a series of significant challenges across all major categories of value analysis.

**Strengths:** Based on the supplied data, there are no identified quantitative strengths that meet the StockValueFinder criteria.

**Weaknesses:** - **Valuation:** The P/E ratio of 45.57 is high, suggesting the stock is expensive relative to its earnings. - **Efficiency:** The ROIC of 1.39% is very low, indicating inefficient use of capital. - **Solvency:** The failure of the interest coverage test and the extremely long debt payback period of 23.26 years suggest significant financial risk and potential difficulty in managing debt obligations. - **Earnings:** The failure of the EPS test indicates a lack of the necessary earnings consistency required for this model. - **Momentum:** The "SELL / AVOID TREND" indicates negative price momentum.

Risks and Limitations

Investors must be aware that biotechnology is a sector prone to high volatility. Quantitative models are based on historical and current data, which cannot account for sudden regulatory changes, clinical trial results, or unexpected shifts in the macroeconomic environment, such as sudden changes in interest rates or government debt levels that might impact liquidity across all sectors.

Furthermore, a 0% score is a reflection of this specific model's parameters. It is a tool for identifying companies that fail to meet strict value and efficiency thresholds; it does not account for qualitative factors like intellectual property or management talent that are not captured in these specific ratios.

Educational Conclusion

Through this analysis of MannKind Corp (MNKD), we have demonstrated how a systematic approach to stock research works. By looking at ROIC, we measure efficiency; by looking at interest coverage and debt payback, we measure safety; by looking at P/E, we measure value; and by looking at EPS, we measure consistency.

When a company fails multiple tests across these diverse categories—as MNKD has done in this screening—it signals to a value-oriented researcher that the risk profile may be disproportionately high relative to the potential for disciplined capital appreciation. Learning to recognize these patterns is a fundamental skill in the pursuit of sound financial education.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.


Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Mac Gemton IV

Mac Gemton IV is a financial research analyst specializing in equity valuation, ETF performance, dividend income strategies, and investment risk assessment. With a disciplined, data-driven approach, he examines company fundamentals, earnings growth, balance-sheet strength, valuation ratios, historical returns, and market trends. His research focuses on identifying financial strengths, potential risks, and long-term investment considerations, transforming complex financial data into clear, practical analysis for everyday investors.

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top